{"gene":"TSPYL1","run_date":"2026-06-10T10:51:56","timeline":{"discoveries":[{"year":2004,"finding":"A homozygous frameshift mutation (457_458insG) in TSPYL1 at codon 153 results in truncation at codon 169, causing loss of the nucleosome assembly protein (NAP) domain. GFP-fusion expression constructs demonstrated that the truncated TSPYL1 protein loses nuclear localization, indicating loss of a nuclear localization signal in addition to the NAP domain.","method":"Sequence analysis of patient DNA, GFP-fusion expression constructs with subcellular localization imaging","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GFP-fusion localization experiment with patient-derived mutant, single lab, two orthogonal methods (sequencing + imaging)","pmids":["15273283"],"is_preprint":false},{"year":2005,"finding":"TSPYL1 (via yeast two-hybrid screen) interacts with the N-terminal region of zinc finger protein 106 (ZFP106), recruiting ZFP106 into TSPYL-positive nucleoplasmic bodies. This recruitment requires a TSPYL domain that is absent in the truncated patient mutant, linking this interaction to the SIDDT disease mechanism.","method":"Yeast two-hybrid screen, co-localization by fluorescence microscopy, deletion analysis","journal":"The international journal of biochemistry & cell biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — yeast two-hybrid interaction plus co-localization imaging, single lab, two orthogonal methods","pmids":["15833274"],"is_preprint":false},{"year":2017,"finding":"TSPYL1 functions as a transcriptional repressor of CYP17A1 and CYP3A4 gene expression. A common TSPYL1 SNP rs3828743 (Pro62Ser) abolishes TSPYL1's ability to suppress CYP3A4 expression, resulting in reduced abiraterone concentrations and increased cell proliferation in prostate cancer cells.","method":"Gene knockdown/overexpression, reporter assays, SNP functional analysis in cell lines, clinical pharmacokinetic data","journal":"Clinical pharmacology and therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown/overexpression with CYP expression readouts plus SNP functional validation, single lab","pmids":["29027195"],"is_preprint":false},{"year":2019,"finding":"TSPYL1 transcriptionally regulates CYP2C19 expression (as a repressor), and the TSPYL1 rs3828743 SNP decreases its suppression of CYP2C19 expression. Additionally, TSPYLs regulate expression of the serotonin transporter SLC6A4, thereby modulating serotonin transport into cells.","method":"Gene knockdown/overexpression, CYP2C19 and SLC6A4 expression assays, serotonin transport assays in cell lines","journal":"Clinical pharmacology and therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional knockdown/overexpression with transporter expression and serotonin transport readouts, single lab","pmids":["31628858"],"is_preprint":false},{"year":2020,"finding":"A truncated TSPYL1 protein lacking the NAP domain (due to frameshift variant p.Val242GlufsTer52) is retained in the Golgi of patient fibroblasts rather than the nucleus (confirmed by cellular fractionation/imaging). TSPYL1-deficient cells display prolonged S and G2 phases with reduced proliferation rates. Proteomic analysis of nuclear extracts identified 24 upregulated and 20 downregulated proteins, with 'regulation of cell cycle' as the top affected pathway. Tspyl1 depletion in zebrafish produced early lethality, defects in neurogenesis, and cardiac dilation.","method":"Whole-exome sequencing, immunofluorescence/subcellular localization of patient fibroblasts, cell cycle analysis (flow cytometry), nuclear proteomics, zebrafish morpholino knockdown","journal":"Human molecular genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (localization, cell cycle analysis, proteomics, zebrafish model) in a single rigorous study; disease-causing variant mechanistically characterized","pmids":["33075815"],"is_preprint":false},{"year":2024,"finding":"TSPYL1 acts as a transcriptional repressor of TGFBR1 and TSPYL2 by partnering with the transcription factor FOXA1 and histone methyltransferase EZH2. Depletion of TSPYL1 increases TGFBR1 expression, upregulates TGFβ signaling, and elevates the protein stability of TSPYL2. TSPYL2, in turn, forms part of the SMAD2/3/4 signal transduction complex upon TGFβ stimulation to execute transcriptional responses including EMT. Depletion of TSPYL2 rescues the EMT phenotype caused by TSPYL1 knockdown in A549 lung carcinoma cells.","method":"siRNA knockdown, co-immunoprecipitation, ChIP assay (FOXA1, EZH2 interaction), Western blot for TGFBR1 and TSPYL2 stability, SMAD2/3/4 complex co-IP, EMT phenotype rescue experiments","journal":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, knockdown rescue epistasis, protein stability assays) in a single study establishing pathway position and binding partners","pmids":["38588050"],"is_preprint":false}],"current_model":"TSPYL1 is a nuclear NAP-domain protein that functions as a transcriptional repressor by partnering with FOXA1 and EZH2 to suppress TGFBR1, TSPYL2, and CYP genes (including CYP3A4 and CYP17A1), thereby restraining TGFβ/SMAD signaling, EMT, and CYP-mediated drug metabolism; loss of TSPYL1's NAP domain (via frameshift mutations) mislocalizes the protein to the Golgi, disrupts cell cycle progression (prolonged S/G2 phases), and in zebrafish causes neurogenesis defects and cardiac dilation consistent with the lethal SIDDT syndrome."},"narrative":{"mechanistic_narrative":"TSPYL1 is a nuclear nucleosome assembly protein (NAP)-domain protein that acts as a transcriptional repressor governing cell-cycle progression, TGFβ/SMAD signaling, and drug-metabolizing gene expression [PMID:33075815, PMID:38588050]. It represses TGFBR1 and TSPYL2 by partnering with the transcription factor FOXA1 and the histone methyltransferase EZH2; loss of TSPYL1 de-represses TGFBR1, amplifies TGFβ signaling, and stabilizes TSPYL2, which joins the SMAD2/3/4 complex to drive transcriptional responses including EMT, an effect reversed by TSPYL2 depletion [PMID:38588050]. TSPYL1 also represses a panel of cytochrome P450 genes including CYP17A1, CYP3A4, and CYP2C19, as well as the serotonin transporter SLC6A4; the common Pro62Ser variant (rs3828743) impairs CYP repression, lowering abiraterone exposure and increasing prostate cancer cell proliferation [PMID:29027195, PMID:31628858]. Frameshift truncations that remove the NAP domain abolish nuclear localization and mislocalize the protein to the Golgi, and TSPYL1-deficient cells show prolonged S and G2 phases with reduced proliferation, while Tspyl1 depletion in zebrafish causes early lethality, neurogenesis defects, and cardiac dilation consistent with the lethal SIDDT syndrome [PMID:15273283, PMID:33075815].","teleology":[{"year":2004,"claim":"Established that a disease-associated frameshift mutation truncates TSPYL1 to remove its NAP domain and an associated nuclear localization signal, defining the molecular basis of SIDDT as loss of nuclear function.","evidence":"Patient DNA sequencing and GFP-fusion subcellular localization of the truncated protein","pmids":["15273283"],"confidence":"Medium","gaps":["Did not define the nuclear function lost","No identification of binding partners or transcriptional targets"]},{"year":2005,"claim":"Identified ZFP106 as a TSPYL1 interaction partner recruited into nucleoplasmic bodies through a domain absent in the disease mutant, linking a specific protein interaction to the SIDDT mechanism.","evidence":"Yeast two-hybrid screen, co-localization imaging, and deletion analysis","pmids":["15833274"],"confidence":"Medium","gaps":["Functional consequence of ZFP106 recruitment unresolved","Interaction not validated by reciprocal endogenous Co-IP"]},{"year":2017,"claim":"Defined TSPYL1 as a transcriptional repressor of CYP17A1 and CYP3A4 and showed a common coding SNP abolishes this repression, connecting TSPYL1 to drug metabolism and prostate cancer pharmacology.","evidence":"Knockdown/overexpression, reporter assays, SNP functional analysis, and clinical pharmacokinetics","pmids":["29027195"],"confidence":"Medium","gaps":["Mechanism of promoter targeting not defined","Direct binding to CYP loci not established"]},{"year":2019,"claim":"Extended TSPYL1 repressor activity to CYP2C19 and to the serotonin transporter SLC6A4, showing the rs3828743 variant weakens repression and altering serotonin transport.","evidence":"Knockdown/overexpression with CYP/SLC6A4 expression and serotonin transport assays","pmids":["31628858"],"confidence":"Medium","gaps":["Co-regulators mediating repression unidentified","In vivo relevance of serotonin transport effect untested"]},{"year":2020,"claim":"Demonstrated that NAP-domain loss mislocalizes TSPYL1 to the Golgi and that TSPYL1 deficiency impairs cell-cycle progression and produces developmental defects in vivo, tying the molecular lesion to cellular and organismal phenotypes.","evidence":"Exome sequencing, patient fibroblast localization, flow-cytometry cell-cycle analysis, nuclear proteomics, and zebrafish morpholino knockdown","pmids":["33075815"],"confidence":"High","gaps":["Transcriptional targets driving cell-cycle delay not pinpointed","Mechanistic link between Golgi mislocalization and loss of function unresolved"]},{"year":2024,"claim":"Placed TSPYL1 in a defined repressor complex with FOXA1 and EZH2 controlling TGFBR1 and TSPYL2, establishing a TSPYL1–TSPYL2 axis that restrains TGFβ/SMAD-driven EMT.","evidence":"siRNA knockdown, Co-IP, ChIP, protein stability assays, and TSPYL2-depletion rescue of EMT in A549 cells","pmids":["38588050"],"confidence":"High","gaps":["Whether the same FOXA1/EZH2 complex governs CYP gene repression untested","Genome-wide TSPYL1 occupancy not mapped"]},{"year":null,"claim":"How TSPYL1's NAP domain mechanistically achieves transcriptional repression and target selectivity, and whether its chromatin/nucleosome activity unifies its CYP, TGFβ, and cell-cycle roles, remains unresolved.","evidence":"No single study in the corpus reconciles the NAP-domain biochemistry with the diverse repressor functions","pmids":[],"confidence":"Medium","gaps":["No direct nucleosome assembly/biochemical activity demonstrated","No structural model of TSPYL1 or its complexes","Mechanism linking NAP-domain loss to Golgi retention unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[2,3,5]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,1,4]},{"term_id":"GO:0005654","term_label":"nucleoplasm","supporting_discovery_ids":[1]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[4]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[5]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[2,3,5]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[4]}],"complexes":[],"partners":["FOXA1","EZH2","TSPYL2","ZFP106"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H0U9","full_name":"Testis-specific Y-encoded-like protein 1","aliases":[],"length_aa":437,"mass_kda":49.2,"function":"","subcellular_location":"Nucleus, nucleolus","url":"https://www.uniprot.org/uniprotkb/Q9H0U9/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TSPYL1","classification":"Not Classified","n_dependent_lines":16,"n_total_lines":1208,"dependency_fraction":0.013245033112582781},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CSNK2B","stoichiometry":0.2},{"gene":"PSME3","stoichiometry":0.2},{"gene":"RPS16","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/TSPYL1","total_profiled":1310},"omim":[{"mim_id":"608800","title":"SUDDEN INFANT DEATH WITH DYSGENESIS OF THE TESTES SYNDROME; SIDDT","url":"https://www.omim.org/entry/608800"},{"mim_id":"604714","title":"TSPY-LIKE 1; TSPYL1","url":"https://www.omim.org/entry/604714"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Nucleoli","reliability":"Supported"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TSPYL1"},"hgnc":{"alias_symbol":[],"prev_symbol":["TSPYL"]},"alphafold":{"accession":"Q9H0U9","domains":[{"cath_id":"3.30.1120.90","chopping":"277-410","consensus_level":"high","plddt":88.2536,"start":277,"end":410},{"cath_id":"1.10.287","chopping":"233-275","consensus_level":"medium","plddt":94.2856,"start":233,"end":275}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H0U9","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H0U9-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H0U9-F1-predicted_aligned_error_v6.png","plddt_mean":60.78},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TSPYL1","jax_strain_url":"https://www.jax.org/strain/search?query=TSPYL1"},"sequence":{"accession":"Q9H0U9","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H0U9.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H0U9/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H0U9"}},"corpus_meta":[{"pmid":"15273283","id":"PMC_15273283","title":"Mapping of sudden infant death with dysgenesis of the testes syndrome (SIDDT) by a SNP genome scan and identification of TSPYL loss of function.","date":"2004","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/15273283","citation_count":105,"is_preprint":false},{"pmid":"9730615","id":"PMC_9730615","title":"Murine and human TSPYL genes: novel members of the TSPY-SET-NAP1L1 family.","date":"1998","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9730615","citation_count":48,"is_preprint":false},{"pmid":"29027195","id":"PMC_29027195","title":"TSPYL Family Regulates CYP17A1 and CYP3A4 Expression: Potential Mechanism Contributing to Abiraterone Response in Metastatic Castration-Resistant Prostate Cancer.","date":"2017","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/29027195","citation_count":33,"is_preprint":false},{"pmid":"15833274","id":"PMC_15833274","title":"Subcellular recruitment by TSG118 and TSPYL implicates a role for zinc finger protein 106 in a novel developmental pathway.","date":"2005","source":"The international journal of biochemistry & cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/15833274","citation_count":27,"is_preprint":false},{"pmid":"19463995","id":"PMC_19463995","title":"Mutations in the TSPYL1 gene associated with 46,XY disorder of sex development and male infertility.","date":"2009","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/19463995","citation_count":14,"is_preprint":false},{"pmid":"31628858","id":"PMC_31628858","title":"Dual Roles for the TSPYL Family in Mediating Serotonin Transport and the Metabolism of Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder.","date":"2019","source":"Clinical pharmacology and therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/31628858","citation_count":14,"is_preprint":false},{"pmid":"22736055","id":"PMC_22736055","title":"Single-nucleotide polymorphisms in the TSPYL-4 and NT5DC1 genes are associated with susceptibility to chronic obstructive pulmonary disease.","date":"2012","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/22736055","citation_count":14,"is_preprint":false},{"pmid":"16418600","id":"PMC_16418600","title":"Genetic investigation of the TSPYL1 gene in sudden infant death syndrome.","date":"2006","source":"Genetics in medicine : official journal of the American College of Medical Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/16418600","citation_count":13,"is_preprint":false},{"pmid":"28847364","id":"PMC_28847364","title":"Spermatogenic phenotype of testis-specific protein, Y-encoded, 1 (TSPY1) dosage deficiency is independent of variations in TSPY-like 1 (TSPYL1) and TSPY-like 5 (TSPYL5): a case-control study in a Han Chinese population.","date":"2018","source":"Reproduction, fertility, and development","url":"https://pubmed.ncbi.nlm.nih.gov/28847364","citation_count":11,"is_preprint":false},{"pmid":"22137496","id":"PMC_22137496","title":"Should TSPYL1 mutation screening be included in routine diagnostics of male idiopathic infertility?","date":"2011","source":"Fertility and sterility","url":"https://pubmed.ncbi.nlm.nih.gov/22137496","citation_count":5,"is_preprint":false},{"pmid":"38588050","id":"PMC_38588050","title":"TSPYL1 as a Critical Regulator of TGFβ Signaling through Repression of TGFBR1 and TSPYL2.","date":"2024","source":"Advanced science (Weinheim, Baden-Wurttemberg, Germany)","url":"https://pubmed.ncbi.nlm.nih.gov/38588050","citation_count":4,"is_preprint":false},{"pmid":"33075815","id":"PMC_33075815","title":"Unravelling the disease mechanism for TSPYL1 deficiency.","date":"2020","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/33075815","citation_count":4,"is_preprint":false},{"pmid":"38380703","id":"PMC_38380703","title":"The effect of genetic variants in the transcription factor TSPYL family on the CYP3A4 mediated cyclosporine metabolism in kidney transplant patients.","date":"2024","source":"Clinical and translational science","url":"https://pubmed.ncbi.nlm.nih.gov/38380703","citation_count":4,"is_preprint":false},{"pmid":"25449952","id":"PMC_25449952","title":"Variants in TSPYL1 are not associated with sudden infant death syndrome in a cohort of deceased infants from Switzerland.","date":"2014","source":"Molecular and cellular probes","url":"https://pubmed.ncbi.nlm.nih.gov/25449952","citation_count":4,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":9458,"output_tokens":1829,"usd":0.027904,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8721,"output_tokens":2552,"usd":0.053703,"stage2_stop_reason":"end_turn"},"total_usd":0.081607,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"A homozygous frameshift mutation (457_458insG) in TSPYL1 at codon 153 results in truncation at codon 169, causing loss of the nucleosome assembly protein (NAP) domain. GFP-fusion expression constructs demonstrated that the truncated TSPYL1 protein loses nuclear localization, indicating loss of a nuclear localization signal in addition to the NAP domain.\",\n      \"method\": \"Sequence analysis of patient DNA, GFP-fusion expression constructs with subcellular localization imaging\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GFP-fusion localization experiment with patient-derived mutant, single lab, two orthogonal methods (sequencing + imaging)\",\n      \"pmids\": [\"15273283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"TSPYL1 (via yeast two-hybrid screen) interacts with the N-terminal region of zinc finger protein 106 (ZFP106), recruiting ZFP106 into TSPYL-positive nucleoplasmic bodies. This recruitment requires a TSPYL domain that is absent in the truncated patient mutant, linking this interaction to the SIDDT disease mechanism.\",\n      \"method\": \"Yeast two-hybrid screen, co-localization by fluorescence microscopy, deletion analysis\",\n      \"journal\": \"The international journal of biochemistry & cell biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — yeast two-hybrid interaction plus co-localization imaging, single lab, two orthogonal methods\",\n      \"pmids\": [\"15833274\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"TSPYL1 functions as a transcriptional repressor of CYP17A1 and CYP3A4 gene expression. A common TSPYL1 SNP rs3828743 (Pro62Ser) abolishes TSPYL1's ability to suppress CYP3A4 expression, resulting in reduced abiraterone concentrations and increased cell proliferation in prostate cancer cells.\",\n      \"method\": \"Gene knockdown/overexpression, reporter assays, SNP functional analysis in cell lines, clinical pharmacokinetic data\",\n      \"journal\": \"Clinical pharmacology and therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown/overexpression with CYP expression readouts plus SNP functional validation, single lab\",\n      \"pmids\": [\"29027195\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TSPYL1 transcriptionally regulates CYP2C19 expression (as a repressor), and the TSPYL1 rs3828743 SNP decreases its suppression of CYP2C19 expression. Additionally, TSPYLs regulate expression of the serotonin transporter SLC6A4, thereby modulating serotonin transport into cells.\",\n      \"method\": \"Gene knockdown/overexpression, CYP2C19 and SLC6A4 expression assays, serotonin transport assays in cell lines\",\n      \"journal\": \"Clinical pharmacology and therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional knockdown/overexpression with transporter expression and serotonin transport readouts, single lab\",\n      \"pmids\": [\"31628858\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A truncated TSPYL1 protein lacking the NAP domain (due to frameshift variant p.Val242GlufsTer52) is retained in the Golgi of patient fibroblasts rather than the nucleus (confirmed by cellular fractionation/imaging). TSPYL1-deficient cells display prolonged S and G2 phases with reduced proliferation rates. Proteomic analysis of nuclear extracts identified 24 upregulated and 20 downregulated proteins, with 'regulation of cell cycle' as the top affected pathway. Tspyl1 depletion in zebrafish produced early lethality, defects in neurogenesis, and cardiac dilation.\",\n      \"method\": \"Whole-exome sequencing, immunofluorescence/subcellular localization of patient fibroblasts, cell cycle analysis (flow cytometry), nuclear proteomics, zebrafish morpholino knockdown\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (localization, cell cycle analysis, proteomics, zebrafish model) in a single rigorous study; disease-causing variant mechanistically characterized\",\n      \"pmids\": [\"33075815\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"TSPYL1 acts as a transcriptional repressor of TGFBR1 and TSPYL2 by partnering with the transcription factor FOXA1 and histone methyltransferase EZH2. Depletion of TSPYL1 increases TGFBR1 expression, upregulates TGFβ signaling, and elevates the protein stability of TSPYL2. TSPYL2, in turn, forms part of the SMAD2/3/4 signal transduction complex upon TGFβ stimulation to execute transcriptional responses including EMT. Depletion of TSPYL2 rescues the EMT phenotype caused by TSPYL1 knockdown in A549 lung carcinoma cells.\",\n      \"method\": \"siRNA knockdown, co-immunoprecipitation, ChIP assay (FOXA1, EZH2 interaction), Western blot for TGFBR1 and TSPYL2 stability, SMAD2/3/4 complex co-IP, EMT phenotype rescue experiments\",\n      \"journal\": \"Advanced science (Weinheim, Baden-Wurttemberg, Germany)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (Co-IP, ChIP, knockdown rescue epistasis, protein stability assays) in a single study establishing pathway position and binding partners\",\n      \"pmids\": [\"38588050\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"TSPYL1 is a nuclear NAP-domain protein that functions as a transcriptional repressor by partnering with FOXA1 and EZH2 to suppress TGFBR1, TSPYL2, and CYP genes (including CYP3A4 and CYP17A1), thereby restraining TGFβ/SMAD signaling, EMT, and CYP-mediated drug metabolism; loss of TSPYL1's NAP domain (via frameshift mutations) mislocalizes the protein to the Golgi, disrupts cell cycle progression (prolonged S/G2 phases), and in zebrafish causes neurogenesis defects and cardiac dilation consistent with the lethal SIDDT syndrome.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TSPYL1 is a nuclear nucleosome assembly protein (NAP)-domain protein that acts as a transcriptional repressor governing cell-cycle progression, TGFβ/SMAD signaling, and drug-metabolizing gene expression [#4, #5]. It represses TGFBR1 and TSPYL2 by partnering with the transcription factor FOXA1 and the histone methyltransferase EZH2; loss of TSPYL1 de-represses TGFBR1, amplifies TGFβ signaling, and stabilizes TSPYL2, which joins the SMAD2/3/4 complex to drive transcriptional responses including EMT, an effect reversed by TSPYL2 depletion [#5]. TSPYL1 also represses a panel of cytochrome P450 genes including CYP17A1, CYP3A4, and CYP2C19, as well as the serotonin transporter SLC6A4; the common Pro62Ser variant (rs3828743) impairs CYP repression, lowering abiraterone exposure and increasing prostate cancer cell proliferation [#2, #3]. Frameshift truncations that remove the NAP domain abolish nuclear localization and mislocalize the protein to the Golgi, and TSPYL1-deficient cells show prolonged S and G2 phases with reduced proliferation, while Tspyl1 depletion in zebrafish causes early lethality, neurogenesis defects, and cardiac dilation consistent with the lethal SIDDT syndrome [#0, #4].\",\n  \"teleology\": [\n    {\n      \"year\": 2004,\n      \"claim\": \"Established that a disease-associated frameshift mutation truncates TSPYL1 to remove its NAP domain and an associated nuclear localization signal, defining the molecular basis of SIDDT as loss of nuclear function.\",\n      \"evidence\": \"Patient DNA sequencing and GFP-fusion subcellular localization of the truncated protein\",\n      \"pmids\": [\"15273283\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not define the nuclear function lost\", \"No identification of binding partners or transcriptional targets\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Identified ZFP106 as a TSPYL1 interaction partner recruited into nucleoplasmic bodies through a domain absent in the disease mutant, linking a specific protein interaction to the SIDDT mechanism.\",\n      \"evidence\": \"Yeast two-hybrid screen, co-localization imaging, and deletion analysis\",\n      \"pmids\": [\"15833274\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of ZFP106 recruitment unresolved\", \"Interaction not validated by reciprocal endogenous Co-IP\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined TSPYL1 as a transcriptional repressor of CYP17A1 and CYP3A4 and showed a common coding SNP abolishes this repression, connecting TSPYL1 to drug metabolism and prostate cancer pharmacology.\",\n      \"evidence\": \"Knockdown/overexpression, reporter assays, SNP functional analysis, and clinical pharmacokinetics\",\n      \"pmids\": [\"29027195\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of promoter targeting not defined\", \"Direct binding to CYP loci not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended TSPYL1 repressor activity to CYP2C19 and to the serotonin transporter SLC6A4, showing the rs3828743 variant weakens repression and altering serotonin transport.\",\n      \"evidence\": \"Knockdown/overexpression with CYP/SLC6A4 expression and serotonin transport assays\",\n      \"pmids\": [\"31628858\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-regulators mediating repression unidentified\", \"In vivo relevance of serotonin transport effect untested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrated that NAP-domain loss mislocalizes TSPYL1 to the Golgi and that TSPYL1 deficiency impairs cell-cycle progression and produces developmental defects in vivo, tying the molecular lesion to cellular and organismal phenotypes.\",\n      \"evidence\": \"Exome sequencing, patient fibroblast localization, flow-cytometry cell-cycle analysis, nuclear proteomics, and zebrafish morpholino knockdown\",\n      \"pmids\": [\"33075815\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional targets driving cell-cycle delay not pinpointed\", \"Mechanistic link between Golgi mislocalization and loss of function unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Placed TSPYL1 in a defined repressor complex with FOXA1 and EZH2 controlling TGFBR1 and TSPYL2, establishing a TSPYL1–TSPYL2 axis that restrains TGFβ/SMAD-driven EMT.\",\n      \"evidence\": \"siRNA knockdown, Co-IP, ChIP, protein stability assays, and TSPYL2-depletion rescue of EMT in A549 cells\",\n      \"pmids\": [\"38588050\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether the same FOXA1/EZH2 complex governs CYP gene repression untested\", \"Genome-wide TSPYL1 occupancy not mapped\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TSPYL1's NAP domain mechanistically achieves transcriptional repression and target selectivity, and whether its chromatin/nucleosome activity unifies its CYP, TGFβ, and cell-cycle roles, remains unresolved.\",\n      \"evidence\": \"No single study in the corpus reconciles the NAP-domain biochemistry with the diverse repressor functions\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct nucleosome assembly/biochemical activity demonstrated\", \"No structural model of TSPYL1 or its complexes\", \"Mechanism linking NAP-domain loss to Golgi retention unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [2, 3, 5]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 1, 4]},\n      {\"term_id\": \"GO:0005654\", \"supporting_discovery_ids\": [1]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [5]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [2, 3, 5]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"FOXA1\", \"EZH2\", \"TSPYL2\", \"ZFP106\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"faith_supported":4,"faith_total":4,"faith_pct":100.0}}